AU4855299A - Ns4a-ns3 catalytic domain of hepatitis c - Google Patents

Ns4a-ns3 catalytic domain of hepatitis c

Info

Publication number
AU4855299A
AU4855299A AU48552/99A AU4855299A AU4855299A AU 4855299 A AU4855299 A AU 4855299A AU 48552/99 A AU48552/99 A AU 48552/99A AU 4855299 A AU4855299 A AU 4855299A AU 4855299 A AU4855299 A AU 4855299A
Authority
AU
Australia
Prior art keywords
ns4a
hepatitis
catalytic domain
catalytic
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU48552/99A
Inventor
Marina Bukhtiyarova
Ben M. Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Publication of AU4855299A publication Critical patent/AU4855299A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
AU48552/99A 1998-07-02 1999-07-02 Ns4a-ns3 catalytic domain of hepatitis c Abandoned AU4855299A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9167598P 1998-07-02 1998-07-02
US60091675 1998-07-02
PCT/US1999/015035 WO2000001718A2 (en) 1998-07-02 1999-07-02 Ns4a-ns3 catalytic domain of hepatitis c

Publications (1)

Publication Number Publication Date
AU4855299A true AU4855299A (en) 2000-01-24

Family

ID=22229082

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48552/99A Abandoned AU4855299A (en) 1998-07-02 1999-07-02 Ns4a-ns3 catalytic domain of hepatitis c

Country Status (2)

Country Link
AU (1) AU4855299A (en)
WO (1) WO2000001718A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
EP1951748B1 (en) * 2005-11-11 2013-07-24 Vertex Pharmaceuticals, Inc. Hepatitis c virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
IT1277914B1 (en) * 1995-08-22 1997-11-12 Angeletti P Ist Richerche Bio PROCEDURE TO PRODUCE - IN PURE FORM AND IN HIGH QUANTITIES - POLYPEPTIDES WITH THE PROTEOLYTIC ACTIVITY OF THE NS3 PROTEASE OF HCV, AND
AU1416099A (en) * 1997-11-28 1999-06-16 Schering Corporation Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide

Also Published As

Publication number Publication date
WO2000001718A2 (en) 2000-01-13
WO2000001718A3 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
EP0970386B8 (en) Impedance-to-voltage converter
AU4063400A (en) Catalytic trap and methods of making and using the same
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU5239399A (en) Antisense modulation of g-alpha-13 expression
AU4325199A (en) Antisense modulation of g-alpha-11 expression
AU1536799A (en) Bishydroxyureas as inhibitors of the 5-lipoxygenase
AU3095095A (en) Rna component of telomerase
AU7099198A (en) Use of amantadine for treatment of hepatitis c
AU3789399A (en) Indolicidin analogs and methods of using same
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU2997099A (en) Methods of suppressing microglial activation
AUPP342298A0 (en) Hydraulic fastening of components
AU2333099A (en) Aryloxyanilides and related compounds
AU3717499A (en) Item of cookware
AU6362198A (en) Improved catch basin
AU4855299A (en) Ns4a-ns3 catalytic domain of hepatitis c
AUPP385598A0 (en) Purification of antibodies
AU4691999A (en) Antisense modulation of rhob expression
AU1459500A (en) Dihydropyridine compounds and methods of use
AU5964099A (en) Quantitation of rna
AU1577100A (en) Catalytic process
AU1221101A (en) Antisense modulation of cytohesin-2expression
AU2627999A (en) Novel derivatives of cyclodextrins
AU2542399A (en) Purification of liquids

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase